Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTENSE plaque CT statin trial
2025-522868-32-00Phase 3Authorised
- Sponsor
- Semmelweis University
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis comparing Rosuvastatin (Xeter) with Placebo (2 arms). Primary endpoint: Non-calcified plaque volume at 3 months. Planned start Sep 2025; status: authorised.
02
Drugs
Roliptin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2025-522868-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522868-32-00.